_version_ 1785090540914606080
author Varelas, Christos
Gavriilaki, Eleni
Dolgiras, Panagiotis
Iskas, Michail
Lalagianni, Chrysavgi
Antonia, Syrigou
Papathanasiou, Maria
Marvaki, Anastasia
Vadikolia, Chrysanthi
Mallouri, Despina
Batsis, Ioannis
Bousiou, Zoi
Vardi, Anna
Karavalakis, Georgios
Spyridis, Nikolaos
Panteliadou, Alkistis Kyra
Masmanidou, Marianna
Yannaki, Evangelia
Arsos, Georgios
Geroukis, Triantafillos
Stavrogianni, Niki
Sakellari, Ioanna
author_facet Varelas, Christos
Gavriilaki, Eleni
Dolgiras, Panagiotis
Iskas, Michail
Lalagianni, Chrysavgi
Antonia, Syrigou
Papathanasiou, Maria
Marvaki, Anastasia
Vadikolia, Chrysanthi
Mallouri, Despina
Batsis, Ioannis
Bousiou, Zoi
Vardi, Anna
Karavalakis, Georgios
Spyridis, Nikolaos
Panteliadou, Alkistis Kyra
Masmanidou, Marianna
Yannaki, Evangelia
Arsos, Georgios
Geroukis, Triantafillos
Stavrogianni, Niki
Sakellari, Ioanna
author_sort Varelas, Christos
collection PubMed
description
format Online
Article
Text
id pubmed-10428737
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104287372023-08-17 PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT Varelas, Christos Gavriilaki, Eleni Dolgiras, Panagiotis Iskas, Michail Lalagianni, Chrysavgi Antonia, Syrigou Papathanasiou, Maria Marvaki, Anastasia Vadikolia, Chrysanthi Mallouri, Despina Batsis, Ioannis Bousiou, Zoi Vardi, Anna Karavalakis, Georgios Spyridis, Nikolaos Panteliadou, Alkistis Kyra Masmanidou, Marianna Yannaki, Evangelia Arsos, Georgios Geroukis, Triantafillos Stavrogianni, Niki Sakellari, Ioanna Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428737/ http://dx.doi.org/10.1097/01.HS9.0000975776.53037.73 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Varelas, Christos
Gavriilaki, Eleni
Dolgiras, Panagiotis
Iskas, Michail
Lalagianni, Chrysavgi
Antonia, Syrigou
Papathanasiou, Maria
Marvaki, Anastasia
Vadikolia, Chrysanthi
Mallouri, Despina
Batsis, Ioannis
Bousiou, Zoi
Vardi, Anna
Karavalakis, Georgios
Spyridis, Nikolaos
Panteliadou, Alkistis Kyra
Masmanidou, Marianna
Yannaki, Evangelia
Arsos, Georgios
Geroukis, Triantafillos
Stavrogianni, Niki
Sakellari, Ioanna
PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title_full PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title_fullStr PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title_full_unstemmed PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title_short PB2261: DECREASE IN NEUTROPHIL-LYMPHOCYTE RATIO IMPACTS OVERALL SURVIVAL OF ADULT PATIENTS WITH HODGKIN LYMPHOMA AFTER ANTI-PD1 TREATMENT
title_sort pb2261: decrease in neutrophil-lymphocyte ratio impacts overall survival of adult patients with hodgkin lymphoma after anti-pd1 treatment
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428737/
http://dx.doi.org/10.1097/01.HS9.0000975776.53037.73
work_keys_str_mv AT varelaschristos pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT gavriilakieleni pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT dolgiraspanagiotis pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT iskasmichail pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT lalagiannichrysavgi pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT antoniasyrigou pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT papathanasioumaria pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT marvakianastasia pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT vadikoliachrysanthi pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT mallouridespina pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT batsisioannis pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT bousiouzoi pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT vardianna pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT karavalakisgeorgios pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT spyridisnikolaos pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT panteliadoualkistiskyra pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT masmanidoumarianna pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT yannakievangelia pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT arsosgeorgios pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT geroukistriantafillos pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT stavrogianniniki pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment
AT sakellariioanna pb2261decreaseinneutrophillymphocyteratioimpactsoverallsurvivalofadultpatientswithhodgkinlymphomaafterantipd1treatment